Overview

A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)

Status:
Completed

Trial end date:
2020-03-17

Target enrollment:

Participant gender:

Summary

To assess the efficacy, safety and pharmacokinetics in participants treated with CD11301 gel vs. placebo for early stage CTCL (IA, IB, or IIA).

Phase:

Phase 2

Details

Lead Sponsor:

Galderma R&D